NasdaqCM:CAPR

Stock Analysis Report

Executive Summary

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Capricor Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CAPR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-20.5%

CAPR

0.7%

US Biotechs

0.2%

US Market


1 Year Return

-81.0%

CAPR

5.6%

US Biotechs

12.2%

US Market

Return vs Industry: CAPR underperformed the US Biotechs industry which returned 5.6% over the past year.

Return vs Market: CAPR underperformed the US Market which returned 12.2% over the past year.


Shareholder returns

CAPRIndustryMarket
7 Day-20.5%0.7%0.2%
30 Day-38.4%8.3%3.5%
90 Day-40.1%4.7%6.3%
1 Year-81.0%-81.0%6.5%5.6%14.7%12.2%
3 Year-94.4%-94.4%13.9%10.3%47.8%38.3%
5 Year-95.4%-95.4%4.7%-0.2%62.1%44.1%

Price Volatility Vs. Market

How volatile is Capricor Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Capricor Therapeutics undervalued compared to its fair value and its price relative to the market?

2.57x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CAPR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CAPR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CAPR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CAPR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CAPR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CAPR is good value based on its PB Ratio (2.6x) compared to the US Biotechs industry average (2.8x).


Next Steps

Future Growth

How is Capricor Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

9.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CAPR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CAPR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CAPR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CAPR's revenue is expected to decline over the next 3 years (-14.4% per year).

High Growth Revenue: CAPR's revenue is forecast to decline over the next 3 years (-14.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CAPR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Capricor Therapeutics performed over the past 5 years?

4.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if CAPR has high quality earnings.

Growing Profit Margin: CAPR's current net profit margins (-793.1%) are lower than last year (111.4%).


Past Earnings Growth Analysis

Earnings Trend: CAPR is unprofitable, but has reduced losses over the past 5 years at a rate of 4.9% per year.

Accelerating Growth: Unable to compare CAPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CAPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).


Return on Equity

High ROE: CAPR has a negative Return on Equity (-506.05%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Capricor Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CAPR's short term assets ($6.6M) exceeds its short term liabilities ($1.6M)

Long Term Liabilities: CAPR's short term assets (6.6M) exceeds its long term liabilities (3.4M)


Debt to Equity History and Analysis

Debt Level: CAPR is debt free.

Reducing Debt: CAPR currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: CAPR has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CAPR's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CAPR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CAPR has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.4% each year.


Next Steps

Dividend

What is Capricor Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CAPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CAPR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CAPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CAPR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CAPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Capricor Therapeutics's salary, the management and board of directors tenure and is there insider trading?

4.8yrs

Average management tenure


CEO

Linda Marbán (56yo)

9.8yrs

Tenure

US$377,471

Compensation

Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be ...


CEO Compensation Analysis

Compensation vs Market: Linda's total compensation ($USD377.47K) is about average for companies of similar size in the US market ($USD510.82K).

Compensation vs Earnings: Linda's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.8yrs

Average Tenure

56yo

Average Age

Experienced Management: CAPR's management team is considered experienced (4.8 years average tenure).


Board Age and Tenure

6.0yrs

Average Tenure

67.5yo

Average Age

Experienced Board: CAPR's board of directors are considered experienced (6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.8%.


Management Team

  • Frank Litvack (63yo)

    Executive Chairman

    • Tenure: 0yrs
    • Compensation: US$206.62k
  • Eduardo Marbán

    Co-Founder & Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Linda Marbán (56yo)

    Co-Founder

    • Tenure: 9.8yrs
    • Compensation: US$377.47k
  • Karen Krasney (66yo)

    Executive VP

    • Tenure: 7.7yrs
    • Compensation: US$351.89k
  • Anthony Bergmann (33yo)

    CFO & Corporate Treasurer

    • Tenure: 1.8yrs
    • Compensation: US$273.70k
  • Deborah Ascheim (54yo)

    Consultant

    • Tenure: 1yrs
    • Compensation: US$364.90k
  • Catherine Kelleher

    Consultant

    • Tenure: 0yrs

Board Members

  • George Dunbar (72yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$40.28k
  • Duke Collier (72yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$43.85k
  • Frank Litvack (63yo)

    Executive Chairman

    • Tenure: 0yrs
    • Compensation: US$206.62k
  • David Musket (61yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$54.57k
  • Eduardo Marbán

    Co-Founder & Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Francesco Muntoni

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Linda Marbán (56yo)

    Co-Founder

    • Tenure: 9.8yrs
    • Compensation: US$377.47k
  • Thomas Voit

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Louis Manzo (81yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$36.70k
  • Ron Victor

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Capricor Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Capricor Therapeutics, Inc.
  • Ticker: CAPR
  • Exchange: NasdaqCM
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.431m
  • Shares outstanding: 4.25m
  • Website: https://www.capricor.com

Number of Employees


Location

  • Capricor Therapeutics, Inc.
  • 8840 Wilshire Boulevard
  • 2nd Floor
  • Beverly Hills
  • California
  • 90211
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CAPRNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDNov 2013
4LN2DB (Deutsche Boerse AG)YesNew Common StockDEEURNov 2013

Biography

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/15 00:07
End of Day Share Price2019/11/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.